OneSource Q4FY26: A sharp Q4 rebound, with FY28 guidance held steady

OneSource Specialty Pharma ended FY26 with a strong Q4 recovery after a softer second half. In Q4FY26, consolidated revenue rose to INR 4,282 million, up 47 percent quarter-on-quarter. EBITDA expanded to INR 919 million, more than five times the previous quarter, with margin improving to 21 percent. Adjusted PAT turned positive at INR 390 million versus an adjusted loss in Q3.

For the full year, FY26 revenue was INR 14,216 million, down 2 percent year-on-year. EBITDA declined 35 percent to INR 3,042 million and the EBITDA margin compressed to 21 percent from 32 percent in FY25. Management described FY26 as a transition year, shaped by delayed semaglutide approvals in Canada and a higher cost base as the drug-device combination facility ramped up.

Q4 recovery was broad-based, with semaglutide moving from pipeline to commercialization

Management’s core message was that Q4 was not a narrow rebound. They attributed the sequential recovery to momentum across all service offerings, supported by India’s semaglutide commercial launch late in the quarter. The company also highlighted two back-to-back semaglutide approvals in Canada and referenced new launches in the US injectables and soft-gelatin businesses.

OneSource positioned itself as an early mover in generic GLP-1 drug-device combinations. In the investor presentation, it stated it is the CDMO partner for the first three generic semaglutide approvals in G7 countries, with two approvals in Canada and one in the US. In India, management said partners were present on day one across multiple customer brands, and the presentation noted that OneSource’s partners collectively command around two-thirds of the generic injectable semaglutide market share by value in April 2026.

FY26: building capacity and capabilities ahead of the next leg of growth

The company’s operational update reinforced that FY26 was heavy on groundwork. It reported 31 new MSAs and licensing agreements signed, 18 injectable and softgel product launches, and five new customer logos, taking total customers to 75 plus. It also reported 49 successful regulatory inspections and customer audits across sites.

A key theme was capacity expansion to service a larger commercial pipeline. OneSource disclosed that cartridge capacity expansion is underway at its flagship site, with about USD 80 million committed against the announced USD 100 million capex. The company added 380 plus hires during FY26 to support the ramp-up.

On the earnings call, management stated that the new DDC line is undergoing qualification and is expected to be available for commercialization from the next quarter, with another additional line expected by end of the year, taking total to three lines installed by end of FY27. Management also explained capacity using sterile manufacturing days and highlighted that output depends on batch size, with newer lines designed to support larger batches compared to the existing line.

Alongside DDC, OneSource continued to expand in biologics, sterile injectables, and softgels. The presentation described biologics as a potential next growth engine, citing a fourfold increase in funnel, a partnership with a leading European biosimilar company, and onboarding of a US-based biosimilar player with a pipeline of five plus biosimilars. Management also highlighted a second project with a top three global animal health company. In the call, management indicated biologics contribution should become meaningful by FY28, while commercial manufacturing is expected beyond FY28.

Acquisition paused, guidance reaffirmed

A notable corporate update was the decision to pause the proposed acquisition of two USFDA-approved specialty injectable assets from Steriscience. The scheme had received a no-objection certificate from stock exchanges, but the board decided not to pursue the transaction in its current form after some stakeholders raised concerns on valuation. Management stated it will revisit the deal after both OneSource and the incoming assets deliver their FY28 guidance targets.

Despite FY26 softness, management reaffirmed the FY28 outlook of roughly USD 400 million organic revenue with around 40 percent steady-state EBITDA margin. The company also reiterated a targeted ROCE of greater than 50 percent.

The near-term execution focus is clear. Management expects demand visibility for semaglutide to remain robust, while the constraint is capacity. It also stated that customers are reserving capacity through upfront fees and take-or-pay type contracts.

Takeaways for investors

OneSource’s FY26 numbers reflect a year of transition, with profitability and margins falling from FY25 levels. But Q4FY26 showed a sharp sequential recovery, supported by semaglutide commercialization momentum and operating leverage. The path to FY28 depends on two moving parts that management emphasized repeatedly: timely commissioning and qualification of new DDC lines, and the pace at which partners scale launches across markets.

BlogpostTitle: OneSource Q4FY26: A sharp Q4 rebound, with FY28 guidance held steady BlogpostSlug: onesource-q4fy26 BlogpostCoverImageDescription: An ultra-realistic corporate finance scene showing a clean desk with a laptop displaying a dashboard-style line chart of quarterly revenue rising sharply from Q3 to Q4 and a bar chart of EBITDA expanding strongly, alongside a smaller panel showing FY26 versus FY25 EBITDA margin compression. In the background, a subtle industrial pharmaceutical manufacturing setting with sterile production equipment silhouettes and an abstract capacity expansion progress indicator, under neutral office lighting, professional and data-driven, no logos or text labels. BlogpostShortTitle: OneSource Q4 rebound and FY28 target